Analysts have been eager to weigh in on the Healthcare sector with new ratings on Annovis Bio (ANVS – Research Report), Gilead Sciences (GILD – Research Report) and Omega Therapeutics (OMGA – Research Report).
Annovis Bio (ANVS)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Annovis Bio today and set a price target of $30.00. The company’s shares closed last Monday at $7.28, close to its 52-week low of $5.23.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Annovis Bio with a $25.25 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Gilead Sciences (GILD)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Gilead Sciences, with a price target of $78.00. The company’s shares closed last Monday at $65.94, close to its 52-week low of $64.63.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $82.95 average price target, implying a 27.0% upside from current levels. In a report issued on April 15, Truist Financial also initiated coverage with a Hold rating on the stock with a $82.00 price target.
Omega Therapeutics (OMGA)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Omega Therapeutics today and set a price target of $12.00. The company’s shares closed last Monday at $2.29, close to its 52-week low of $1.30.
According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omega Therapeutics with a $10.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ANVS:
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
- Largest borrow rate increases among liquid names
- Annovis Bio Inc call volume above normal and directionally bullish
- Annovis Bio falls -9.6%
- Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
